INDUSTRY INSIGHTS
Pivoting To Allogeneic CAR-T Therapies With Celyad Oncology’s CMO, Dr. Charlie Morris
Podcast | Cell & Gene
Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
MOST POPULAR NEWS
•
FormaPath Announces The Novel Tissue Biopsy Grossing Platform: nToto
Nucleus Genomics Launches To Bring Whole-Genome Sequencing To The Public
Scientists Close In On TB Blood Test Which Could Detect Millions Of Silent Spreaders
CMS Designates The NavDx Test As An Advanced Diagnostic Laboratory Test (ADLT)
STEMCELL Technologies Announces FDA De Novo Classification For Its EasySep CD138 Positive Selection Kit
Bostongene Recognized As Designated Lab For The ComboMATCH Precision Medicine Clinical Trial
SOLUTIONS
Brochure: Biacore X100
Bioprocess Online
